Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Graphite Bio logo — Creating a future where the word 'incurable' no longer exist...

Graphite Bio

Creating a future where the word 'incurable' no longer exists.

Founded 2020 United States South San Francisco, United States 2 employees Acquired Total: $433.00M Biotechnology

General Information

Company Name Graphite Bio
Founded Year 2020
Location United States South San Francisco, United States
Employees 2
Industries Biotechnology
Funding Stage Acquired
Business Model B2B, D2C, B2D
Revenue Model Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Graphite Bio. To contact Graphite Bio, visit graphitebio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Graphite Bio compare?

A PDF of Graphite Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Graphite Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Graphite Bio

Graphite Bio, founded in 2020 and headquartered in the United States, is a clinical-stage biotechnology company revolutionizing the field of gene editing. The company aims to eliminate the term "incurable," as captured by their slogan, "Creating a future where the word 'incurable' no longer exists."

Graphite Bio is pioneering a groundbreaking approach to precision gene editing with its proprietary UltraHDR™ platform. This technology leverages the power of high-efficiency precision DNA repair to go beyond conventional CRISPR capabilities, offering a potential leap forward in treating serious and life-threatening diseases. Co-founded by esteemed scientists Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D., the company is set on transforming healthcare outcomes by effectively correcting genetic mutations and offering novel cures.

In its most recent funding event, Graphite Bio received an acquisition investment on 01 March 2024 from Merz Therapeutics. This strategic infusion is expected to bolster the company's efforts to expand its curative therapies to a broader patient base.

Business keywords: gene editing, precision medicine, CRISPR technology, homology-directed repair, gene therapy, genome correction, sickle cell disease, DNA repair, disease cure, clinical-stage biotechnology, therapeutic innovation, novel conditioning regimens, genetic mutations, next-generation therapies

Services & Products

Development and commercialization of VIZZ ophthalmologic solution
Providing pharmaceutical solutions for presbyopia

Target Customers

Individuals with presbyopia Healthcare professionals specializing in ophthalmology Optometrists Ophthalmologists

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition Undisclosed 1
Merz Therapeutics
Merz Therapeutics
01 Mar 2024
IPO $238.00M -
01 Jun 2021
Series B $150.00M 14
RA Capital Management Venrock OrbiMed
RA Capital Management, Venrock +12
01 Mar 2021
Series A $45.00M 2
Versant Ventures Samsara BioCapital
Versant Ventures, Samsara BioCapital
01 Sep 2020

Graphite Bio Alternatives & Competitors

View All Alternatives
Graphite Bio vs
Editas Medicine
Editas Medicine United States

What If You Could Repair Broken Genes?

IPO
178 employees
Biotechnology
Compare Graphite Bio vs Editas Medicine
Graphite Bio vs
Prime Medicine, Inc.
Prime Medicine, Inc. United States

Delivering on the promise of Prime Editing

IPO
187 employees
Biotechnology, Life Sciences
Compare Graphite Bio vs Prime Medicine, Inc.
Graphite Bio vs
Acrigen Biosciences
Acrigen Biosciences United States

Developing life-saving genetic therapies using our proprietary precision gene editing technology

Seed
6 employees
Biotechnology, Life Sciences
Also compare with: Graphite Bio vs Caribou Biosciences Caribou Biosciences Graphite Bio vs Tune Therapeutics Tune Therapeutics View all alternatives

FAQ About Graphite Bio

Creating a future where the word 'incurable' no longer exists.
Graphite Bio was founded in 2020.
Graphite Bio is headquartered in South San Francisco, United States.
Graphite Bio operates in Biotechnology. Its work centres on gene editing, precision medicine, CRISPR technology and homology-directed repair. Its customers include Individuals with presbyopia, Healthcare professionals specializing in ophthalmology and Optometrists.
Graphite Bio has a B2B, D2C and B2D business model. Its revenue comes from Product Sales and Licensing.
Graphite Bio has approximately 2 employees.
Graphite Bio has completed 4 funding rounds, raising a total of $433.00M. The latest funding stage is Acquired.
Graphite Bio offers: Development and commercialization of VIZZ ophthalmologic solution, Providing pharmaceutical solutions for presbyopia.
Top alternatives and competitors to Graphite Bio include Editas Medicine, Prime Medicine, Inc., Acrigen Biosciences, Specific Biologics, Caribou Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Graphite Bio and Editas Medicine are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Graphite Bio, https://bouncewatch.com/company/graphite-bio, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes